Ser462
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser462  -  AML1 iso8 (human)

Site Information
AEGSHSNsPTNMAPS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454402

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , mutation of modification site ( 1 , 2 , 3 ) , phospho-antibody ( 2 )
Disease tissue studied:
leukemia ( 1 , 3 ) , chronic myelogenous leukemia ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 3 ) , ERK2 (human) ( 3 )
Treatments:
cell cycle regulated ( 2 ) , nocodazole ( 2 ) , PD98059 ( 3 ) , phorbol_ester ( 2 , 3 ) , purvalanol ( 2 )

Downstream Regulation
Effects of modification on biological processes:
cell differentiation, induced ( 1 )

References 

1

Yoshimi M, et al. (2012) Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol 42, 1044-50
22531928   Curated Info

2

Wang S, Zhang Y, Soosairajah J, Kraft AS (2007) Regulation of RUNX1/AML1 during the G2/M transition. Leuk Res 31, 839-51
17023045   Curated Info

3

Zhang Y, Biggs JR, Kraft AS (2004) Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279, 53116-25
15475366   Curated Info